Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22 |
filingDate |
2004-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d296d687ff78267be95ab26264a2a44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ae9c14798797532ee44de42cc26ee6d |
publicationDate |
2005-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2005053994-A1 |
titleOfInvention |
Human DNase |
abstract |
This invention relates to a novel human deoxyribonuclease, referred to as LS-DNase, that is relatively resistant to inhibition by actin, as compared to human DNase I. The invention provides nucleic acid sequences encoding LS-DNase, thereby enabling the production of LS-DNase by recombinant DNA methods in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of LS-DNase. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150051883-A |
priorityDate |
1996-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |